QURE — uniQure N.V.
8 mentions in the last 24 hours · 0.07% of all mentions
Why people talked about QURE (2026-11-02)
- The FDA accepted the Biologics License Application for AMT-130, a gene therapy for Huntington's disease.
- Priority Review designation was granted, setting the PDUFA date for May 1, 2027.
- The drug retains Breakthrough Therapy, RMAT, and Fast Track designations.
| Bluesky | 5 | community |
| ApeWisdom (Reddit) | 2 | community |
| SEC EDGAR 8-K | 1 | filings |